公开(公告)号：US12195556B2

公开(公告)日：2025-01-14

申请号：US16008430

申请日：2018-06-14

Applicant: Ludwig Institute for Cancer Research Ltd.

Inventor： Immanuel F. Luescher ,  Julien Schmidt ,  Philippe Guillaume ,  Danijel Dojcinovic

IPC: A61K39/385 ,  A61K39/00 ,  C07K14/74 ,  C07K17/00 ,  C12N5/0783

Abstract: Some aspect of this disclosure provide reversible MHC protein multimers, and methods of using such multimers in the detection and/or isolation of specific T-cells or T-cell populations. Because reversible MHC multimers can efficiently be dissociated, the time of MHC binding to T-cell receptors, and, thus, T-cell receptor-mediated T-cell activation can be minimized. The use of reversible MHC multimers as provided herein, accordingly, allows for the detection and isolation of bona fide antigen-specific CD8+ T cells without inducing activation dependent cell death, including rare, therapeutically valuable T-cells expressing T-cell receptors binding tumor antigens with high affinity. Methods for the production and use of reversible multimers are also provided.

公开(公告)号：US12173086B2

公开(公告)日：2024-12-24

申请号：US17501486

申请日：2021-10-14

Applicant: Arrowhead Pharmaceuticals, Inc.

Inventor： Aaron Almeida ,  Zhen Li ,  Erik W. Bush ,  Tao Pei ,  Agnieszka Glebocka ,  Anthony Nicholas ,  Jeffrey Carlson ,  Matthew Fowler-Watters

IPC: A61K38/04 ,  A61K31/713 ,  A61K38/08 ,  A61K47/60 ,  A61K47/64 ,  C07K5/00 ,  C07K5/062 ,  C07K7/00 ,  C07K7/06 ,  C07K16/00 ,  C07K16/28 ,  C07K17/00 ,  C12N15/113

Abstract: Integrin ligands having serum stability and affinity for αvβ6 integrins are described. Compositions comprising αvβ6 integrin ligands having serum stability and having affinity for αvβ6 integrins and methods of using them are also described.

公开(公告)号：US20240279272A1

公开(公告)日：2024-08-22

申请号：US18438790

申请日：2024-02-12

Applicant: Impact Proteomics ,  University of Pittsburgh Medical Center

Inventor： Jonathan Minden ,  Dana Ascherman

IPC: C07K1/22 ,  C07K17/00 ,  C07K19/00 ,  C12N9/76

CPC classification number: C07K1/22 ,  C07K17/00 ,  C07K19/00 ,  C12N9/6427 ,  C12Y304/21004

Abstract: Materials and methods for isolating self-antigen polypeptides are provided.

公开(公告)号：US20240117325A1

公开(公告)日：2024-04-11

申请号：US18390220

申请日：2023-12-20

Applicant: Panasonic Intellectual Property Management Co, Ltd.

Inventor： Noriyuki Hatsugai ,  Fumiya WAYAMA ,  Yasuaki OKUMURA

IPC: C12N9/02 ,  C07K14/47 ,  C07K17/00

CPC classification number: C12N9/0051 ,  C07K14/47 ,  C07K17/00 ,  C07K2319/00 ,  C12Y108/07002

Abstract: A fusion protein obtained by fusing a ferredoxin-thioredoxin reductase and thioredoxin via a linker peptide. The linker peptide includes glycine (G) and serine (S).

公开(公告)号：US11912756B2

公开(公告)日：2024-02-27

申请号：US17236978

申请日：2021-04-21

Applicant: NantBio, Inc.

Inventor： Clifford Anders Olson

IPC: C40B40/08 ,  C07K16/00 ,  C12N15/10 ,  C12N15/62 ,  C12N15/11 ,  C07K17/00 ,  C07K16/24 ,  C07K16/28 ,  C40B50/06 ,  C40B30/04

CPC classification number: C07K16/005 ,  C07K16/244 ,  C07K16/2827 ,  C07K17/00 ,  C12N15/1037 ,  C12N15/1041 ,  C12N15/1062 ,  C12N15/111 ,  C12N15/62 ,  C40B40/08 ,  C40B50/06 ,  C07K2317/515 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2317/94 ,  C40B30/04

Abstract: Compositions, methods and uses of high-diversity nucleic acid library that encodes a plurality of antibodies or antibody fragments are presented. The high-diversity nucleic acid library comprises or is derived from (1) a VH-CDR1/2 sub-library, (2) a plurality of VH-CDR3 sub-libraries, and (3) a VL sub-library, each of which comprises a plurality of members. Preferably, each member of the sub-libraries comprises at least one random cassette that has a plurality of degenerate base positions. In an especially preferred embodiment, at least portions of at least two members of the VH-CDR1/2 sub-library, the plurality of VH-CDR3 sub-libraries, and the VL sub-library are recombined to form an expression library member in an expression library, where each member of the expression library encodes a distinct antibody or antibody fragment.

公开(公告)号：US20230303629A1

公开(公告)日：2023-09-28

申请号：US18020797

申请日：2021-08-17

Applicant: GRIFOLS DIAGNOSTIC SOLUTIONS INC.

Inventor： EFRAIN CEH PAVIA ,  ELISABETE NASCIMENTO ,  ELIZABETH A. BOOTH ,  ZEBULON LAPOINT ,  CHARLES HOLZ ,  TRISTAN WASLEY ,  JODY MELTON WITT

IPC: C07K14/005 ,  C07K17/00 ,  C07K1/107 ,  C12N7/00

CPC classification number: C07K14/005 ,  C07K17/00 ,  C07K1/1075 ,  C12N7/00 ,  C07K2319/00 ,  C12N2770/20022 ,  C12N2770/20051

Abstract: A fusion protein includes a SARS-CoV-2 nucleocapsid N-terminal domain and/or a SARS-CoV-2 nucleocapsid C-terminal domain, wherein the fusion protein lacks the SARS-CoV-2 nucleocapsid aggregation domain.

公开(公告)号：US11733234B2

公开(公告)日：2023-08-22

申请号：US15648339

申请日：2017-07-12

Applicant: Emulate Inc.

Inventor： Daniel Levner ,  Kyung Jin Jang ,  Jacob Fraser ,  S. Jordan Kerns ,  Antonio Varone ,  Dongeun Huh

IPC: C12N5/00 ,  C12N5/02 ,  A61K38/00 ,  C07K2/00 ,  C07K4/00 ,  C07K5/00 ,  C07K7/00 ,  C07K14/00 ,  C07K16/00 ,  C07K17/00 ,  G01N33/50 ,  C07K14/78 ,  C12N5/071 ,  C12M3/06 ,  C12M1/00 ,  C12M1/12 ,  C12N5/077

CPC classification number: G01N33/5032 ,  C07K2/00 ,  C07K14/78 ,  C12M23/16 ,  C12M23/20 ,  C12M25/02 ,  C12N5/0018 ,  C12N5/0068 ,  C12N5/067 ,  C12N5/0658 ,  G01N33/5014 ,  C12N2500/32 ,  C12N2521/00 ,  C12N2533/30 ,  C12N2533/50 ,  C12N2533/52 ,  C12N2533/54 ,  C12N2533/90 ,  C12N2535/10 ,  C12N2537/10 ,  G01N33/5044

Abstract: Compositions, devices and methods are described for improving adhesion, attachment, and/or differentiation of cells in a microfluidic device or chip. In one embodiment, one or more ECM proteins are covalently coupled to the surface of a microchannel of a microfluidic device. The microfluidic devices can be stored or used immediately for culture and/or support of living cells such as mammalian cells, and/or for simulating a function of a tissue, e.g., a liver tissue, muscle tissue, etc. Extended adhesion and viability with sustained function over time is observed.

公开(公告)号：US11672850B2

公开(公告)日：2023-06-13

申请号：US17729290

申请日：2022-04-26

Applicant: Think Therapeutics, Inc.

Inventor： David Kenneth Gifford ,  Brandon Carter

IPC: A61K39/00 ,  A61K38/00 ,  A61K38/10 ,  A61K38/08 ,  A61K38/04 ,  C07K5/00 ,  C07K7/00 ,  C07K16/00 ,  C07K17/00 ,  C07K7/06 ,  C07K7/08 ,  A61P35/00 ,  A61K48/00

CPC classification number: A61K39/00116 ,  A61K38/08 ,  A61K38/10 ,  A61K39/001152 ,  A61K39/001158 ,  A61P35/00 ,  C07K7/06 ,  C07K7/08 ,  A61K48/00 ,  A61K2039/812 ,  A61K2039/82 ,  A61K2039/86

Abstract: Described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 19 to 50. Also described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 141 to 272. Also described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 273 to 322. Also described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 354 to 458.

公开(公告)号：US11666625B2

公开(公告)日：2023-06-06

申请号：US16789196

申请日：2020-02-12

Applicant: Allegro Pharmaceuticals, LLC

Inventor： Michael John Mackel ,  John Park

IPC: A61K38/08 ,  A61K38/12 ,  A61K38/00 ,  A61P9/10 ,  A61P27/02 ,  C07K5/00 ,  C07K7/00 ,  C07K16/00 ,  C07K17/00 ,  A61K9/08 ,  A61K38/17 ,  A61K51/06 ,  A61K51/08 ,  A61L27/22 ,  A61L31/04 ,  A61K47/64 ,  A61K38/07 ,  A61K9/06

CPC classification number: A61K38/12 ,  A61K9/08 ,  A61K38/07 ,  A61K38/08 ,  A61K38/1709 ,  A61K47/64 ,  A61K51/065 ,  A61K51/082 ,  A61K51/088 ,  A61L27/227 ,  A61L31/043 ,  C07K7/00 ,  A61K9/06 ,  A61L2300/252

Abstract: Compounds comprising R-G-Cysteic Acid (i.e., R-G-NH—CH(CH2—SO3H)COOH or Arg-Gly-NH—CH(CH2—SO3H)COOH) and derivatives thereof, including pharmaceutically acceptable salts, hydrates, stereoisomers, multimers, cyclic forms, linear forms, drug-conjugates, pro-drugs and their derivatives. Also disclosed are methods for making and using such compounds including methods for inhibiting cellular adhesion to RGD binding sites or delivering other diagnostic or therapeutic agents to RGD binding sites in human or animal subjects.

公开(公告)号：US11660354B2

公开(公告)日：2023-05-30

申请号：US16463865

申请日：2017-11-29

Applicant: Memorial Sloan Kettering Cancer Center ,  Cornell University ,  The Curators of the University of Missouri

Inventor： Michelle S. Bradbury ,  Thomas P. Quinn ,  Barney Yoo ,  Wolfgang Weber ,  Karim Touijer ,  Howard Scher ,  Kai Ma ,  Ulrich Wiesner

IPC: A61K49/00 ,  A61K51/08 ,  A61K51/12 ,  C07K7/02 ,  C07K17/00 ,  G01N33/574

CPC classification number: A61K49/0067 ,  A61K49/0002 ,  A61K49/0056 ,  A61K51/08 ,  A61K51/088 ,  A61K51/1244 ,  C07K7/02 ,  C07K17/00 ,  G01N33/57434

Abstract: Described herein are novel conjugates containing an inhibitor (e.g., a PSMA inhibitor, e.g., a gastrin-releasing peptide receptor inhibitor) and metal chelator that are covalently attached to a macromolecule (e.g., a nanoparticle, a polymer, a protein). Such conjugates exhibit distinct properties over the free, unbound inhibitor/chelator construct.